Novo CEO eyes cheap biotech market: "Of course the price matters, but there are other factors, too"

Big biotech price drops could create acquisition opportunities similar to the firm’s record-breaking purchase of Dicerna, says Novo Nordisk CEO Lars Fruergaard Jørgensen, explaining that the company is looking at a wide range of disease areas for potential purchases.
Lars Fruergaard Jørgensen, CEO at Novo Nordisk | Photo: Stine Bidstrup/ERH
Lars Fruergaard Jørgensen, CEO at Novo Nordisk | Photo: Stine Bidstrup/ERH
by ANDREAS LØNSTRUP, translated by daniel pedersen & catherine brett

Novo Nordisk expects future research and development expenditures will increase at a higher rate than the company’s top line growth. This will ensure that one or more successors are ready once the pharmaceutical firm’s current growth engine, semaglutide, loses its patent.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading